Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker
Eli Lilly
[March 06, 2025]
Makers of the popular obesity treatments Wegovy and Zepbound are
cutting prices for people without insurance.
Danish drugmaker Novo Nordisk said Wednesday that it will drop prices
23% for all doses of Wegovy. The new monthly price of $499, down from
$650, takes effect immediately.
Novo said the new pricing is available to both the uninsured and people
who have insurance that doesn't cover the weight-loss drugs.
Last week, Eli Lilly said it would cut the monthly price of its starter
dose of Zepbound to $349. The U.S. drugmaker also is making larger doses
available for $499 through its self-pay program.
Patients start taking the injectable drugs at smaller dose levels and
then increase the amount over time.
The price cuts come as supplies improve. The U.S. Food and Drug
Administration has moved both drugs off its list of medicines in
shortage. The agency has said compounding pharmacies and other entities
that have been allowed to make off-brand, cheaper copies of the drugs
during the shortage will have to wind down production.
[to top of second column]
|
Donna Cooper holds up a dosage of Wegovy, a drug used for weight
loss, at her home in Front Royal, Va., on Friday, March 1, 2024. (AP
Photo/Amanda Andrade-Rhoades, File)
 Wegovy and Zepbound are part of a GLP-1 class of treatments that has
shown unprecedented results for helping people shed weight by
decreasing appetite and boosting feelings of fullness. Sales of the
drugs have soared.
All contents © copyright 2025 Associated Press. All rights reserved |
